DE69126727D1 - Warm-behandelte IGM-Antikörper-Zusammensetzungen - Google Patents

Warm-behandelte IGM-Antikörper-Zusammensetzungen

Info

Publication number
DE69126727D1
DE69126727D1 DE69126727T DE69126727T DE69126727D1 DE 69126727 D1 DE69126727 D1 DE 69126727D1 DE 69126727 T DE69126727 T DE 69126727T DE 69126727 T DE69126727 T DE 69126727T DE 69126727 D1 DE69126727 D1 DE 69126727D1
Authority
DE
Germany
Prior art keywords
igm
heat treated
igm antibody
antibody compositions
concentrates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69126727T
Other languages
English (en)
Other versions
DE69126727T2 (de
Inventor
Grace C Tsay
Gary Jesmok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of DE69126727D1 publication Critical patent/DE69126727D1/de
Application granted granted Critical
Publication of DE69126727T2 publication Critical patent/DE69126727T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69126727T 1990-04-03 1991-03-21 Warm-behandelte IGM-Antikörper-Zusammensetzungen Expired - Lifetime DE69126727T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/504,161 US5256771A (en) 1990-04-03 1990-04-03 Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation

Publications (2)

Publication Number Publication Date
DE69126727D1 true DE69126727D1 (de) 1997-08-14
DE69126727T2 DE69126727T2 (de) 1997-10-23

Family

ID=24005109

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69126727T Expired - Lifetime DE69126727T2 (de) 1990-04-03 1991-03-21 Warm-behandelte IGM-Antikörper-Zusammensetzungen

Country Status (9)

Country Link
US (3) US5256771A (de)
EP (1) EP0450412B1 (de)
JP (1) JP3591782B2 (de)
AT (1) ATE155042T1 (de)
CA (1) CA2039387C (de)
DE (1) DE69126727T2 (de)
DK (1) DK0450412T3 (de)
ES (1) ES2104625T3 (de)
GR (1) GR3024910T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
PL1648427T3 (pl) * 2003-05-16 2014-05-30 Mayo Found Medical Education & Res Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM
GB0425537D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) * 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
EP3275897A1 (de) 2016-07-27 2018-01-31 Biotest AG Verfahren zur herstellung von immunoglobulinzusammensetzungen
EP3607091A4 (de) * 2017-04-07 2021-01-20 IGM Biosciences, Inc. Modifizierte menschliche konstante igm-regionen zur modulation der komplementabhängigen zytolyseeffektorfunktion
UY39318A (es) * 2020-07-10 2022-02-25 Grifols Worldwide Operations Ltd Procedimiento para obtener una composicion que comprende inmunoglobulina m derivada de plasma humano

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2527064C3 (de) * 1975-06-18 1979-11-15 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität
DE2835843A1 (de) * 1978-08-16 1980-02-28 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten gammaglobulinloesung
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
JPS56147724A (en) * 1980-04-18 1981-11-16 Teijin Ltd Igm derivative and immunoglobulin preparation for intravenous injection containing said compound as effective component
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
EP0085747B2 (de) * 1982-02-08 1990-05-30 Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate

Also Published As

Publication number Publication date
ATE155042T1 (de) 1997-07-15
JPH04221321A (ja) 1992-08-11
EP0450412A1 (de) 1991-10-09
GR3024910T3 (en) 1998-01-30
US5256771A (en) 1993-10-26
CA2039387C (en) 2002-02-19
DE69126727T2 (de) 1997-10-23
JP3591782B2 (ja) 2004-11-24
US5612033A (en) 1997-03-18
DK0450412T3 (da) 1998-02-16
EP0450412B1 (de) 1997-07-09
US5510465A (en) 1996-04-23
ES2104625T3 (es) 1997-10-16
CA2039387A1 (en) 1991-10-04

Similar Documents

Publication Publication Date Title
Dziarski Preferential induction of autoantibody secretion in polyclonal activation by peptidoglycan and lipopolysaccharide. I. In vitro studies.
DE69429723T2 (de) Stressproteine und ihre verwendung
ATE245446T1 (de) Dualer träger für immunogene konstrukte
CA2132953A1 (en) Monospecific polyclonal antibodies to shiga-like toxins
DE69126727D1 (de) Warm-behandelte IGM-Antikörper-Zusammensetzungen
ES2059640T3 (es) Procedimiento para la fabricacion de un preparado de inmunoglobulina policlonal administrable por via intravenosa con alto contenido de igm.
ATE128732T1 (de) Antigenkonstrukte von ''major histocompatibility complex'' klasse i antigenen mit spezifischen trägermolekülen, ihre herstellung und verwendung.
KR880701108A (ko) 면역조절 조성물 및 이들의 용도
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
Klinman et al. Equine antihapten antibody II. The γG (7Sγ) components and their specific interaction
EP0550020A3 (en) Anti-human ige monoclonal antibodies
DE10299038I2 (de) Pl{ttchen-spezifisches Chim{risches immunglobulin.
Grant et al. Reversed in vitro anaphylaxis induced by anti-IgG: specificity of the reaction and comparison with antigen-induced histamine release
FI934145A (fi) Omformade monoklonala antikroppar mot en immunoglobulinisotyp
Gold et al. Experimental studies on the mechanism of induction of anti-nuclear antibodies by procainamide
DE3851492D1 (de) Ein gattungsspezifisches Listeria-Antigen, identifiziert durch monoklonale Antikörper.
Wilkerson et al. Anti‐A isoagglutinins in two blood type B cats are IgG and IgM
Zikán Interactions of pig Fabμ and Fabα fragments with protein a from Staphylococcus aureus
Kondoh et al. Elimination of undesirable immunoglobulin contaminants including aggregated IgG from γ-globulin preparations by jackfruit lectin affinity chromatography
Stux et al. Heterogeneity of rabbit homologous skin sensitizing antibodies: IgE and a new subclass IgGa
Beernink et al. Proteins adhering to Escherichia coli after exposure to guinea-pig serum
Warner et al. Quantitative Analysis of Spleen Cell and Immunoglobulin Allotype Composition of (CBAxCBA/H-T6)→ C57BL/6 Allophenic Mice
Ramsay et al. A human serum factor (antibody) against altered human serum albumin
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
TH13147EX (th) อนุพันธ์ของฮีสตามีนและวิธีการใช้มันเพื่อเป็นตัวเปลี่ยนแปลงแบบอิมมูน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition